Background. Stereotactic large-core needle biopsy (SLCNB) is a minimally invasive method for histological diagnosis of nonpalpable breast disease. We studied differences in cancer prevalence between a group of women referred through the national screening program and a non-screening group, and assessed whether the validity of SLCNB differed between these groups.
Introduction
The national breast cancer screening program is designed to screen asymptomatic women to detect malignancies at an earlier, nonpalpable stage, in order to reduce breast-cancer associated morbidity and mortality [1] [2] [3] [4] [5] . In The Netherlands, all women aged 50-70 (and since 1998, 50-75) years are invited to participate [6, 7] . Essential in the concept of screening is that all women participating are by definition asymptomatic.
Since most of the discovered mammographic abnormalities are nonpalpable, confirmation of the diagnosis is a challenge for the surgeon these women are referred to. Diagnostic wire-localised open breast biopsy has long been the reference test for nonpalpable breast disease. However, in the last decade, various minimally invasive diagnostic procedures have been developed [8] [9] [10] . Recently, we have tested the stereotactic large core needle biopsy (SLCNB) in a Dutch prospective multicenter trial, the COBRA study (COre Biopsy after RAdiological localisation) [11] . In a group of 972 consecutive women with 1029 nonpalpable mammographic abnormalities SLCNB was performed to determine the histological diagnosis. In each patient, SLCNB was followed by surgical excision (wire localised excision biopsy for nonmalignant lesions, breast conserving treatment or mastectomy for malignant lesions) to compare the initial diagnosis with that of the gold standard. The sensitivity and specificity of the new technique were 97 and 99%, respectively, and thus are comparable to surgical biopsy [11] [12] [13] .
Sixty percent of women included in the COBRA cohort were referred by the national screening program. Consequently, 40% were women with some motive other than an age-induced screening invitation to have their mammogram taken, including a personal or family history of breast cancer, perceived changes in their breast or anxiety. The purpose of this study was to compare these two groups, different in background of referral, with regard to prevalence of cancer and possible consequences for the accuracy of SLCNB. Our hypothesis was that the prevalence of carcinoma would be higher in the screening group.
As has been described before, diagnostic test parameters vary across subpopulations within a certain population [14] . We compared the two groups (screening vs. non-screening) to evaluate if the results with SLCNB obtained in the COBRA study may be applied with equal validity to different subpopulations within the cohort of patients with nonpalpable breast lesions.
Patients and methods

Study population
Data was used from the COBRA study. The methods and results of this study are described elsewhere [11] . For the purpose of the present study we categorised the patients in two groups: one group referred by the national screening program ('screening', n = 511 lesions) and one consisting of patients with a specific motive for mammographic surveillance ('non-screening', n = 339 lesions). Demographic information, relevant medical history, breast cancer risk factors, mammographic findings, and histological factors were prospectively collected and compared between the two groups.
Accuracy of large-core needle biopsy
We evaluated the diagnostic accuracy of large-core needle biopsy using a methodology adapted from Burbank and Parker [15] .
Histological diagnoses of the core biopsy specimens were divided into five categories: normal breast tissue (i.e., not explanatory for the mammographic lesion), benign breast disease, high-risk lesions, DCIS, and invasive breast cancer. Histological diagnoses of the surgical specimens were divided into the same categories.
High-risk lesions were those known to have a high prevalence of carcinoma on excision biopsy (atypical ductal hyperplasia (ductal or lobular) and lobular carcinoma in situ) [16] [17] [18] . In cases of such a high-risk diagnosis on large-core needle biopsy an open breast biopsy is generally recommended [19, 20] .
Subsequently, the predictive value of a 'normal breast tissue' diagnosis, the predictive value of a 'benign' diagnosis, the high-risk underestimate rate and ductal carcinoma in situ (DCIS) underestimate rate as well as the sensitivity and specificity rates were calculated and compared between the subgroups.
The predictive value of a 'normal breast tissue' diagnosis was defined as the proportion of lesions diagnosed as 'normal' on large-core needle biopsy that did not reveal carcinoma (DCIS or invasive) at excision biopsy. Similarly, the predictive value of a 'benign' diagnosis was defined as the proportion of lesions with a benign diagnosis on large-core needle biopsy that proved to be benign after excision biopsy. The high-risk underestimate rate was defined as the proportion of lesions diagnosed as high-risk by largecore needle biopsy that was upgraded to DCIS or invasive cancer in the surgical specimen. The DCIS underestimate rate was defined as the proportion of lesions diagnosed as DCIS by large-core needle biopsy that was upgraded to invasive cancer in the surgical specimen.
The sensitivity rate was defined as the proportion of malignancies that was identified as abnormal (hence, warranting surgical excision) by SLCNB and the specificity rate was defined as the proportion of benign lesions that was not categorised as carcinoma (DCIS or invasive carcinoma) by SLCNB.
Statistical analysis
Statistical analysis was performed with use of the Statistical Package for the Social Sciences 7.5 (SPSS Inc. Chicago, IL). Continuous data were tested using the Student's t-test. Nominal data were tested by means of the Chi-square test.
Results
Study population
Between April 1997 and February 2000, 972 consecutive patients with 1029 nonpalpable mammographic lesions were included in the COBRA study. For 850 of the evaluable 858 lesions (99%) the background of referral for mammographic examination was retrieved. Five hundred eleven lesions were included in the 'screening' group, and 339 in the 'non-screening' group. The characteristics of these patients and lesions are presented in Table 1 . Reasons for women outside the national screening program to seek mammographic examination are presented in Table 2 .
Breast cancer prevalence
The histological diagnosis found at SLCNB is presented in Table 3 . The prevalence of carcinoma varied significantly between the 'screening' group (64.0%) and the 'non-screening' group (49.6%) (p < 0.05). Since the threshold of participation in the national screening program in The Netherlands is 50 years of age we studied cancer prevalence for women 50 years and older separately. In the 'screening' group, all but 10 woman were 50 years or older; these 10 woman would turn 50 in the calendar year of their first screening visit. Within the 'non-screening' group, the prevalence of carcinoma was 57.2% (115/201) for women aged 50 years and older, compared to 38.4% (53/138) for the group aged <50 years (p < 0.01). Comparing only women aged 50 years or older between 'screening' and the 'non-screening' group, there was no significant difference in breast cancer prevalence (64 vs. 57%, respectively).
Predictive values, sensitivity, and specificity
The predictive value of a 'normal breast tissue' diagnosis, the predictive value of a 'benign' diagnosis, the high-risk underestimate rate and the DCIS underestimate rate are presented in Table 4 . There were no significant differences in these parameters between the two groups. On a total of 327 malignancies in the 'screening' group, five lesions would have been diagnosed as benign, and these patients would not have received adequate therapy. This resulted in a sensitivity rate of 98.5% (95%CI 96.5-99.5). In the 'nonscreening' group this was 95.2% (95%CI 90.8-97.9) (160/168).
In the screening group, four times malignant disease (DCIS or invasive cancer, IC) was found at core biopsy, while only benign disease was found at surgical excision (4/184). For the 'non-screening group', one of 171 lesions was incorrectly diagnosed as malignant. After revision by an expert panel (consisting of three specialized breast pathologists and two specialized breast radiologists) it was concluded that the pathologist had incorrectly diagnosed these needle biopsies as malignant. These five patients would have been over-treated and hence the findings were called 'false positives'. This resulted in specificities of 97.8% (95%CI 94.5-99.4) for the 'screening' group versus 99.4% (95%CI 96.8-100) for the 'non-screening' group (p > 0.05).
Discussion
Our current study shows that in a group of consecutive patients referred for histological examination of a mammographically detected nonpalpable lesion, as many as 40% (339/850) is referred from outside the national screening program. This is the first study comparing lesions of patients referred outside the national screening program to screen-detected lesions. Women seeking mammographic examination outside the national screening program have an increased prevalence of riskfactors for, or symptoms suggestive of breast cancer. However, prevalence of carcinoma was lower in this subgroup. A possible explanation could be that both the patient (seeking help) and her doctor (referring her for histological examination) perceive an increased risk, and do not want to miss breast cancer; hence referral is made at a lower degree of suspicion in comparison with asymptomatic women from the screening program. This is especially true for women <50 years, since the prevalence of breast cancer in older women is comparable to the results of the breast cancer screening program.
With the increasing knowledge about breast cancer, and the known positive effects of screening on morbidity and mortality, the awareness of women towards breast examination is growing, thereby inducing an increase in the number of nonpalpable lesions detected. Also, because of the detection of breast cancer susceptibility genes such as BRCA1 and 2, there may be an increase in the number of young women referred for risk assessment and counseling. At the same time, as more women survive breast cancer, they demand close surveillance, which leads to an increase of women seeking mammographic surveillance outside the national screening program.
The diagnostic accuracy of any test used is influenced by the prevalence of disease. Specifically, the risk of finding cancer despite a benign diagnosis on SLCNB increases when the prevalence of carcinoma is higher in the population under study (examined), resulting in a higher false negative rate [12] . Before applying test results to a new (sub)population, the prevalence of breast cancer should be assessed. In doing so, no differences were found for any of the main outcome parameters describing the accuracy of SLCNB.
In conclusion, stereotactic large core needle biopsy is an accurate diagnostic test for evaluating nonpalpable mammographic abnormalities both in women referred from the national screening program and in women referred outside screening. Careful monitoring of the implementation of this new diagnostic technique in The Netherlands is mandatory to ensure patients' safety.
